VNS in drug resistant epilepsy: preliminary report on a small group of patients.
BACKGROUND
In 1997 Vagus Nerve Stimulation (VNS) received approval from the US Food and Drug Administration (FDA) as an adjunctive therapy in the treatment of medically intractable partial epilepsy in people aged 12 years and older who are ineligible for resective epilepsy surgery. Although the exact mechanisms of action are unknown, the use of VNS with children has increased, including those younger than 12 years of age, or those with generalized epilepsy.


METHODS
We describe the outcome for the first group of nine patients, aged 8-28 years, who had pharmaco-resistant epilepsy and were treated with VNS. During the follow up, we gradually and slowly increased the parameters of the stimulation in order to assess the efficacy of VNS even at parameters which would usually be considered "non-therapeutic", along with possible side effects and changes in quality of life.


RESULTS
At the last follow, up 1 patient was "seizures free", 3 were "very good responders", 3 were "good responders" and 2 were "non responders". We obtained an initial seizure reduction with low stimulation parameters, the highest current reached being 2.00 mA. This observation supports the possibility that, for younger patients, lower stimulation intensities than those commonly used in clinical practice for adults can be therapeutic. We also wanted to underline the reduction in seizure frequency (approximately 91.7%) and the reduction in seizure duration (> 50%) in the patients affected by drug-resistant absence epilepsy. Adverse effects were mild, tolerable and, in most of cases, easily resolved by adjusting the stimulation parameters. Hoarseness of voice was the most frequent side effect. The improvements in the quality of life are relevant and seem to be independent of the VNS effect in controlling seizures.


CONCLUSIONS
Our small experience seems to confirm the efficacy and safety of VNS in drug resistant partial and generalized epilepsy in developing age groups.
Franzoni
Emilio
E
Child Neuropsychiatry Unit, Bologna University, Italy. emilio.franzoni@unibo.it
Gentile
Valentina
V
Colonnelli
Maria Chiara
MC
Brunetto
Daniela
D
Cecconi
Ilaria
I
Iero
Luisa
L
Moscano
Filomena C
FC
Cordelli
Duccio M
DM
Marchiani
Valentina
V
D000293:Adolescent; D000328:Adult; D002648:Child; D004351:Drug Resistance; D004567:Electrodes, Implanted; D004827:Epilepsy / Q000523:psychology / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D011788:Quality of Life; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D055536:Vagus Nerve Stimulation / Q000379:methods*; D055815:Young Adult
Seizure. 2006 Oct;15(7):483-90
16899378
Neurosurg Rev. 2008 Jul;31(3):291-7
18446391
Epilepsy Res. 2009 Feb;83(2-3):249-56
19124226
Seizure. 2006 Oct;15(7):491-503
16859931
Epilepsia. 2007 Nov;48(11):2187-90
17666074
Epilepsy Res. 2000 Dec;42(2-3):203-10
11074193
Epilepsia. 1989 Jul-Aug;30(4):389-99
2502382
Epilepsia. 2009 May;50(5):1220-8
19170732
Childs Nerv Syst. 2006 Sep;22(9):1167-9
16718501
Neurosurg Focus. 2008 Sep;25(3):E9
18759633
Epilepsy Res. 2006 Aug;70 Suppl 1:S5-10
16822650
Seizure. 2009 May;18(4):275-8
19101178
Epilepsia. 2005 Nov;46(11):1796-801
16302860
Acta Neurol Scand Suppl. 2007;187:55-8
17419830
Childs Nerv Syst. 2002 Feb;18(1-2):61-6
11935246
Epilepsy Behav. 2006 Feb;8(1):246-9
16343997
Epilepsy Behav. 2001 Aug;2(4):343-50
12609211